inHEART raises fresh funds to expand treatments for cardiac arrhythmia

3 July 2020 (Last Updated July 3rd, 2020 12:34)

France-based inHEART has secured additional funding to support the development of artificial intelligence (AI), medical imaging and numerical simulations of cardiac arrhythmias.

inHEART raises fresh funds to expand treatments for cardiac arrhythmia
inHEART will also use the fund to support its commercial development in Europe and to foray into the US market. Credit: Luke MacQueen and Michael Rosnach, Harvard University.

France-based inHEART has secured additional funding to support the development of artificial intelligence (AI), medical imaging and numerical simulations of cardiac arrhythmias.

The company has raised $4.2m in a financing round led by Elaia, a venture capital company focused on European digital and deep-tech startups.

inHEART plans to use the proceeds to accelerate its commercial development in Europe and to foray into the US market.

inHEART CEO and co-founder Jean-Marc Peyrat said: “We are very happy to have Elaia joining inHEART in this adventure not only for its financial support but also for the dynamism and the expertise of its team in developing startups in healthcare.

“Elaia and inHEART share the same ambition to create a major player in cardiac electrophysiology, a €5bn market with healthcare giants such as Johnson & Johnson, Abbott, Boston Scientific or Medtronic.”

The company offers a Cloud-based software solution that converts preoperative medical images into a 3D digital twin of the patient’s heart.

It allows the cardiologist to better plan the procedure and assists in navigating instruments in the patient’s heart. The solution reduces procedure duration and failure rates considerably.

Existing treatment solutions for patients with arrhythmia are not optimal, whether considering drugs, implantable devices or even catheter ablation procedures, the company noted.

Approximately 40% of the patients with ventricular arrhythmias undergo a repeat procedure due to recurrence.

The company is a spin-off from IHU Liryc, which specialises in cardiac electrophysiology, and Inria, a digital science and technology company.

It was founded by an experienced team of scientists and physicians, including AI and cardiac modelling expert MaximeSermesant, radiologist Hubert Cochet and cardiologist Pierre Jaïs.